Robin Jones to Antibiotics, Antineoplastic
This is a "connection" page, showing publications Robin Jones has written about Antibiotics, Antineoplastic.
Connection Strength
2.583
-
Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial. Clin Cancer Res. 2021 07 15; 27(14):3861-3866.
Score: 0.741
-
Subgroup analysis of older patients treated within the randomized phase 3 doxorubicin versus doxorubicin plus evofosfamide (SARC021) trial. J Geriatr Oncol. 2020 04; 11(3):463-469.
Score: 0.656
-
Anthracycline cardiotoxicity. Expert Opin Drug Saf. 2006 Nov; 5(6):791-809.
Score: 0.275
-
Clinical and pathological absence of cardiotoxicity after liposomal doxorubicin. Lancet Oncol. 2004 Sep; 5(9):575-7.
Score: 0.236
-
Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial. JAMA. 2020 04 07; 323(13):1266-1276.
Score: 0.174
-
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2017 08; 18(8):1089-1103.
Score: 0.144
-
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016 Jul 30; 388(10043):488-97.
Score: 0.134
-
Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. Eur J Cancer. 2009 Nov; 45(17):2930-4.
Score: 0.084
-
Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity. Expert Rev Cardiovasc Ther. 2008 Nov; 6(10):1311-7.
Score: 0.079
-
Use of endomyocardial biopsy to assess anthracycline-induced cardiotoxicity. Lancet Oncol. 2005 Feb; 6(2):67.
Score: 0.061